A Phase 4 interventional study of Brimonidine in Rosacea, sponsored by Galderma R&D. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-01.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.
Among the 11 studies testing brimonidine in Rosacea, this one is the 6th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 4, and was the 7th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2014.
This study's enrollment of 205 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 205 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 12th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2014, is one of 9 in phase 4, and was the 22nd registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing brimonidine in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brimonidine topical gel, 0.33%
Drug: Brimonidine
Also known as: Mirvaso Gel
Pre-Treatment Clinician Erythema Assessment (CEA)
The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.
Time frame: 14 days (Day 1 (Baseline), Day 7, and Day 14/Exit)
Subject Facial Redness Questionnaire
Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)
Time frame: 14 days (Day 1 (Baseline) and Day 14/Exit)
Subject Treatment Satisfaction Questionnaire
Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)
Time frame: 14 days (Day 14/Exit)
Facial Redness Visual Analog Scale (VAS)
The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS
Time frame: 14 days (Day 1 (Baseline), Day 14/Exit)
Inflammatory Lesions
Change from baseline in facial inflammatory lesion count
Time frame: 14 days (Day 1 (Baseline) and Day 14/Exit)
| Milestone | Mirvaso Gel |
|---|---|
| Started | 205 |
| Treated | 181 |
| Completed | 176 |
| Not completed | 29 |
The number and percent of subjects in each CEA score category at each visit. CEA was conducted at the screening/baseline visit and all subsequent visits prior to the study drug application.
| Participants | Mirvaso Gel |
|---|---|
| Day 1 (Baseline) — Clear Skin | 0 |
| Day 1 (Baseline) — Almost Clear | 0 |
| Day 1 (Baseline) — Mild Erythema | 7 |
| Day 1 (Baseline) — Moderate Erythema | 144 |
| Day 1 (Baseline) — Severe Erythema | 30 |
| Day 1 (Baseline) — Missing | 0 |
| Day 7 — Clear Skin | 3 |
| Day 7 — Almost Clear | 18 |
| Day 7 — Mild Erythema | 39 |
| Day 7 — Moderate Erythema | 84 |
| Day 7 — Severe Erythema | 24 |
| Day 7 — Missing | 13 |
| Day 14 — Clear Skin | 4 |
| Day 14 — Almost Clear | 25 |
| Day 14 — Mild Erythema | 39 |
| Day 14 — Moderate Erythema | 86 |
| Day 14 — Severe Erythema | 27 |
| Day 14 — Missing | 0 |
Facial Redness Questionnaire at Day 1 and Day 14 (Mean Number of Subjects Who's Responses Indicate They Were/Were Not Bothered By Facial Redness, Across All 11 Facial Redness Questions)
| Participants | Mirvaso Gel |
|---|---|
| Not Bothered (Mean [SD], Day 1, Baseline) | 75.3 ± 39.4 |
| Bothered (Mean [SD], Day 1, Baseline) | 104.7 ± 40.3 |
| Missing (Day 1, Baseline) | 1 ± 0 |
| Not Bothered (Mean [SD], Day 14) | 112.6 ± 28.9 |
| Bothered (Mean [SD], Day 14) | 67.3 ± 26.2 |
| Missing (Day 14) | 1.1 ± .3 |
Mean Subject Treatment Satisfaction at Day 14 (Average Response Across 12 Questions)
| Participants | Mirvaso Gel |
|---|---|
| Satisfied Participants (Mean [SD]) | 127.3 ± 22.2 |
| Dissatisfied Participants (Mean [SD]) | 52.7 ± 22.2 |
| Missing | 1.0 ± 0.0 |
The number and percent of subjects in each transformed response category for the in-office subject reported facial redness VAS
| Participants | Mirvaso Gel |
|---|---|
| Day 1 — None | 1 |
| Day 1 — Very Mild | 31 |
| Day 1 — Mild | 57 |
| Day 1 — Moderate | 48 |
| Day 1 — Severe | 38 |
| Day 1 — Very Severe | 6 |
| Day 14 — None | 1 |
| Day 14 — Very Mild | 63 |
| Day 14 — Mild | 45 |
| Day 14 — Moderate | 44 |
| Day 14 — Severe | 22 |
| Day 14 — Very Severe | 6 |
Change from baseline in facial inflammatory lesion count
| lesions | Mirvaso Gel |
|---|---|
| Day 1: Lesions | .6 ± 1.2 |
| Day 14: Lesions | 1.5 ± 4.4 |
| Day 14: Change From Baseline | 1 ± 3.9 |
Collected over 29 Days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mirvaso Gel | — | 3/181 (1.7%) | 68/181 (37.6%) |
| Event | Mirvaso Gel |
|---|---|
| myocardial infarctionCardiac disorders | 1/181 |
| PericarditisCardiac disorders | 1/181 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 1/181 |
| Event | Mirvaso Gel |
|---|---|
| condition aggravatedGeneral disorders | 33/181 |
| rosaceaSkin and subcutaneous tissue disorders | 21/181 |
| ErythemaSkin and subcutaneous tissue disorders | 7/181 |
| nasopharyngitisInfections and infestations | 6/181 |
| feeling hotGeneral disorders | 4/181 |
ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment
| Age, Categorical(Participants) | Mirvaso Gel |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 143 |
| >=65 years | 38 |
| Age, Continuous(years) | Mirvaso Gel |
|---|---|
| Mean | 52.4 (22.0 to 85.0) |
| Sex: Female, Male(Participants) | Mirvaso Gel |
|---|---|
| Female | 136 |
| Male | 45 |
| Region of Enrollment(Participants) | Mirvaso Gel |
|---|---|
| United States | 181 |
The record gives a start of Sep 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine